Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

1. Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment

Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment CBT and treatment resistant schizophrenia Dissemination Centre Discover Portal NIHR DC Discover Cognitive behavioural therapy may not work for people with schizophrenia who haven’t completely responded to drug treatment Published on 20 November 2018 doi: Cognitive behavioural therapy does not improve residual symptoms for people taking clozapine for schizophrenia (...) . Clozapine is the gold-standard antipsychotic that is used when others have not worked. This NIHR-funded UK trial included 487 adults who had been taking clozapine for on average five years but were still symptomatic. Participants received either weekly cognitive behavioural therapy for nine months alongside usual treatment for schizophrenia or usual treatment alone. Usual treatment included clozapine or other medication and care from secondary, community or inpatient mental health services. There were

NIHR Dissemination Centre2018

2. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial

Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial 30251622 2018 09 25 1472-1465 2018 Sep 25 The British journal of psychiatry : the journal of mental science Br J Psychiatry Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. 1-11 10.1192/bjp.2018.167 Obesity is a major challenge (...) for people with schizophrenia.AimsWe assessed whether STEPWISE, a theory-based, group structured lifestyle education programme could support weight reduction in people with schizophrenia. In this randomised controlled trial (study registration: ISRCTN19447796), we recruited adults with schizophrenia, schizoaffective disorder or first-episode psychosis from ten mental health organisations in England. Participants were randomly allocated to the STEPWISE intervention or treatment as usual. The 12-month

EvidenceUpdates2018

3. Chlorpromazine versus piperacetazine for schizophrenia.

Chlorpromazine versus piperacetazine for schizophrenia. BACKGROUND: Schizophrenia is a severe mental disorder with a prevalence of about 1% among the general population. It is listed among the top 10 causes of disability-adjusted life years (DALYs) worldwide. Antipsychotics are the mainstay treatment. Piperacetazine has been reported to be as clinically effective as chlorpromazine, a well established 'benchmark' antipsychotic, for people with schizophrenia. However, the side effect profiles (...) of these antipsychotics differ and it is important that an evidence base is available comparing the benefits, and potential harms of these two antipsychotics. OBJECTIVES: To assess the clinical and side effects of chlorpromazine for people with schizophrenia and schizophrenia-like psychoses in comparison with piperacetazine. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (6 June 2015 and 8 October 2018) which is based on regular searches of CINAHL, CENTRAL, BIOSIS, AMED, Embase, PubMed

Cochrane2018

4. Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia

Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Signal - Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Dissemination Centre Discover Portal NIHR DC Discover Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Published on 14 November 2017 For adults with schizophrenia who continue to have symptoms despite treatment with the antipsychotic drug clozapine, adding (...) but does not specify any particular drug. Amisulpride is often used in practice, but to date, there had not been much evidence on which to base this decision. Only 68 people with this severe form of schizophrenia were recruited instead of the expected 230, so the ability to detect any clinically significant differences between the groups is reduced. Share your views on the research. Why was this study needed? About 220,000 people in England and Wales have a diagnosis of schizophrenia. In 2007

NIHR Dissemination Centre2018

5. Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia.

Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. BACKGROUND: Schizophrenia is a severe mental health condition that is characterised by positive symptoms, such as hallucinations and delusions; negative symptoms, such as flattened affect, thought disorder (disrupted speech), and lack of motivation; and cognitive symptoms, such as problems with memory and attention. Schizophrenia can occur as an isolated episode, or as a recurring cycle (...) of remission and relapse, and is associated with impairment in psychosocial and occupational functioning.Although antipsychotic drugs are the main treatment for people with schizophrenia, in most countries mental health services usually provide a range of add-on interventions, including occupational therapy. This is a complex intervention designed to support and enable continued participation in daily life through engagement in activities and occupations meaningful to the individual. Occupational

Cochrane2018

6. Culturally adapted Family Intervention (CaFI) for African-Caribbean people diagnosed with schizophrenia and their families: a mixed-methods feasibility study of development, implementation and acceptability

Culturally adapted Family Intervention (CaFI) for African-Caribbean people diagnosed with schizophrenia and their families: a mixed-methods feasibility study of development, implementation and acceptability Culturally adapted Family Intervention (CaFI) for African-Caribbean people diagnosed with schizophrenia and their families: a mixed-methods feasibility study of development, implementation and acceptability Journals Library An error occurred retrieving content to display, please try again (...) . >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} It proved feasible to culturally adapt and test family intervention with African-Caribbean people with schizophrenia and their families, and the study yielded high rates of recruitment, attendance, retention

NIHR HTA programme2018

7. Schizophrenia

Schizophrenia Top results for schizophrenia - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for schizophrenia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

8. Schizophrenia

Schizophrenia Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

Trip Evidence Maps2018

9. Fluphenazine (oral) versus placebo for schizophrenia.

Fluphenazine (oral) versus placebo for schizophrenia. BACKGROUND: Fluphenazine is one of the first drugs to be classed as an 'antipsychotic' and has been widely available for five decades. OBJECTIVES: To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia. To evaluate any available economic studies and value outcome data. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (23 July 2013, 23 December 2014, 9 November 2016 and 28 (...) December 2017 ) which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. There is no language, date, document type, or publication status limitations for inclusion of records in the register. SELECTION CRITERIA: We sought all randomised controlled trials comparing oral fluphenazine with placebo relevant to people with schizophrenia. Primary outcomes of interest were global state and adverse effects. DATA COLLECTION AND ANALYSIS

Cochrane2018

10. Mirtazapine adjunct for people with schizophrenia.

Mirtazapine adjunct for people with schizophrenia. BACKGROUND: Many individuals who have a diagnosis of schizophrenia experience a range of distressing and debilitating symptoms. These can include positive symptoms (such as delusions, hallucinations, disorganised speech), cognitive symptoms (such as trouble focusing or paying attention or using information to make decisions), and negative symptoms (such as diminished emotional expression, avolition, alogia, and anhedonia). Antipsychotic drugs (...) are often only partially effective, particularly in treating negative symptoms, indicating the need for additional treatment. Mirtazapine is an antidepressant drug that when taken in addition to an antipsychotic may offer some benefit for negative symptoms. OBJECTIVES: To systematically assess the effects of mirtazapine as adjunct treatment for people with schizophrenia. SEARCH METHODS: The Information Specialist of Cochrane Schizophrenia searched the Cochrane Schizophrenia Group's Study-Based Register

Cochrane2018

11. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia.

Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. BACKGROUND: Many people with schizophrenia do not respond to an initially prescribed antipsychotic drug. In such cases, one treatment strategy could be to increase the antipsychotic dose; and another strategy could be to switch to a different antipsychotic drug. OBJECTIVES: To examine the efficacy of increasing the antipsychotic dose versus switching the antipsychotic drug in the treatment of non (...) -responsive people with schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017). We examined references of all included studies for further trials. SELECTION CRITERIA: All relevant randomised controlled trials (RCTs) comparing increasing the antipsychotic dose versus switching to a different antipsychotic drug for people with schizophrenia who have not responded to their initial antipsychotic treatment. DATA COLLECTION

Cochrane2018

12. Increasing antipsychotic dose for non response in schizophrenia.

Increasing antipsychotic dose for non response in schizophrenia. BACKGROUND: Many people with schizophrenia do not reach a satisfactory clinical response with a standard dose of an initially prescribed antipsychotic drug. In such cases, clinicians face the dilemma of increasing the antipsychotic dose in order to enhance antipsychotic efficacy. OBJECTIVES: To examine the efficacy of increasing antipsychotic dose compared to keeping the same dose in the treatment of people with schizophrenia who (...) have not responded (as defined in the individual studies) to an initial antipsychotic drug trial. We also examine the adverse effects associated with such a procedure. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017). We examined references of all included studies for further trials. SELECTION CRITERIA: All relevant randomised controlled trials (RCTs), reporting useable data, comparing increasing the antipsychotic dose

Cochrane2018

13. Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance

Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance Relative to SSRI users, SSRI–statin users have fewer psychiatric hospital contacts and no increase in suicidal behaviour or all-cause mortality | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts

Evidence-Based Mental Health2018

14. Cognitive therapy for schizophrenia

Cognitive therapy for schizophrenia Cognitive therapy for schizophrenia Cognitive therapy for schizophrenia Leas B, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Leas B, Umscheid CA. Cognitive therapy for schizophrenia. Philadelphia: Center for Evidence-based Practice (CEP). 2018 Final publication URL Indexing Status Subject (...) indexing assigned by CRD MeSH Cognitive Therapy; Humans; Schizophrenia Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2@uphs.upenn.edu AccessionNumber 32018000158 Date abstract record published 16/04/2018 Health Technology Assessment (HTA) database Copyright © 2018

Health Technology Assessment (HTA) Database.2018

15. Brexpiprazole (Rexulti) - schizophrenia

Brexpiprazole (Rexulti) - schizophrenia Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated to include

Health Canada - Drug and Health Product Register2018

16. Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia

Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia NIHR DC | Signal - Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Published on 14 November 2017 For adults with schizophrenia who continue to have symptoms despite treatment with the antipsychotic drug (...) in these circumstances but does not specify any particular drug. Amisulpride is often used in practice, but to date, there had not been much evidence on which to base this decision. Only 68 people with this severe form of schizophrenia were recruited instead of the expected 230, so the ability to detect any clinically significant differences between the groups is reduced. Share your views on the research. Why was this study needed? About 220,000 people in England and Wales have a diagnosis of schizophrenia. In 2007

NIHR Dissemination Centre2018

17. Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City

Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro- Psychiatric Hospital, Benin City Felicia Ibironke Thomas, Sunday Osasu Olotu and Joyce Ohiole Omoaregba Background Non-attendancetoclinicappointmentsisassociatedwithpoorer treatment outcomes (...) . There is a dearth of information about missed first clinic appointments among patients with schizo- phrenia in Nigeria. Aims Todeterminetheprevalence,correlatesandreasonsformissed first appointment among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City, Nigeria. Method Across-sectionaldescriptivestudyamong275out-patientswith schizophrenia, using the Mini International Neuro-Psychiatric Interview and the Brief Psychiatric Rating Scale. Results The prevalence of missed first

BJPsych open2018 Full Text: Link to full Text with Trip Pro

18. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics ORIGINAL RESEARCH ARTICLE Economic Impact in Medicaid Bene?ciaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics Marie-He ´le `ne Lafeuille 1 • Neeta Tandon 2 • Sean Tiggelaar 1 • Rhiannon Kamstra 1 • Patrick Lefebvre 1 • Edward Kim (...) 2 • Yong Yue 2 • Kruti Joshi 2 Published online: 23 January 2018 The Author(s) 2018. This article is an open access publication Abstract Objective The objective of this study was to compare persistence, costs, and healthcare resource utilization in patients with schizophrenia and cardiometabolic comor- bidities treated with once-monthly paliperidone palmitate or an oral atypical antipsychotic. Methods Medicaid data from six states (07/2009–03/2015) were used to identify adults

Drugs - real world outcomes2018 Full Text: Link to full Text with Trip Pro

19. Schizophrenia

Schizophrenia Schizophrenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Schizophrenia Last reviewed: August 2018 Last updated: June 2018 Summary An illness characterised by a co-occurrence of at least two of the following symptoms: hallucinations, delusions, disorganised speech, disorganised/catatonic behaviour, or negative symptoms occurring for a significant period of time during a 1-month period and associated (...) psychosis. Initially, patients are usually referred by family members. As the illness progresses, patients tend to self-refer or are brought in by a case manager or law enforcement officer. Antipsychotic therapy and psychosocial interventions are effective for most patients, but to varying degrees. Suicidal tendency is one of the most dangerous complications. The lifetime risk of suicide is around 5%. The risk is highest at the onset of the illness. Definition Schizophrenia is an illness characterised

BMJ Best Practice2018